Department of Rheumatology and Immunology, State Key Laboratory of Virology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
Autophagy. 2024 Dec;20(12):2785-2803. doi: 10.1080/15548627.2024.2390814. Epub 2024 Aug 17.
Rabies virus causes an estimated 59,000 annual fatalities worldwide and promising therapeutic treatments are necessary to develop. In this study, affinity tag-purification mass spectrometry was employed to delineate RABV glycoprotein and host protein interactions, and PDIA3/ERP57 was identified as a potential inhibitor of RABV infection. PDIA3 restricted RABV infection with follow mechanisms: PDIA3 mediated the degradation of RABV G protein by targeting lysine 332 via the selective macroautophagy/autophagy pathway; The PDIA3 interactor, AP3B1 (adaptor related protein complex 3 subunit beta 1) was indispensable in PDIA3-triggered selective degradation of the G protein; Furthermore, PDIA3 competitively bound with NCAM1/NCAM (neural cell adhesion molecule 1) to block RABV G, hindering viral entry into host cells. PDIA3 190-199 aa residues bound to the RABV G protein were necessary and sufficient to defend against RABV. These results demonstrated the therapeutic potential of biologics that target PDIA3 or utilize PDIA3 190-199 aa peptide to treat clinical rabies. aa: amino acids; ANXA2: annexin A2; AP-MS: affinity tag purification-mass spectrometry; AP3B1: adaptor related protein complex 3 subunit beta 1; ATP6V1A: ATPase H transporting V1 subunit A; ATP6V1H: ATPase H transporting V1 subunit H; BafA1: bafilomycin A1; CHX: cycloheximide; co-IP: co-immunoprecipitation; DDX17: DEAD-box helicase 17; DmERp60: endoplasmic reticulum p60; EBOV: Zaire ebolavirus virus; EV: empty vector; GANAB: glucosidase II alpha subunit; G protein: glycoprotein; GRM2/mGluR2: glutamate metabotropic receptor 2; HsPDIA3: protein disulfide isomerase family A member 3; IAV: influenza virus; ILF2: interleukin enhancer binding factor 2; KO: knockout; MAGT1: magnesium transporter 1; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MmPDIA3: protein disulfide isomerase associated 3; NCAM1/NCAM: neural cell adhesion molecule 1; NGFR/p75NTR: nerve growth factor receptor; NGLY1: N-glycanase 1; OTUD4: OTU deubiquitinase 4; PDI: protein disulfide isomerase; PPIs: protein-protein interactions; RABV: rabies virus; RUVBL2: RuvB like AAA ATPase 2; SCAMP3: secretory carrier membrane protein 3; ScPdi1: S protein disulfide isomerase 1; SLC25A6: solute carrier family 25 member 6; SQSTM1/p62: sequestosome 1; VSV: vesicular stomatitis virus.
狂犬病病毒在全球范围内每年导致约 59000 人死亡,因此有必要开发有前途的治疗方法。在这项研究中,亲和标签纯化质谱法被用于描绘狂犬病病毒糖蛋白和宿主蛋白的相互作用,PDIA3/ERP57 被鉴定为潜在的狂犬病病毒感染抑制剂。PDIA3 通过以下机制限制狂犬病病毒感染:PDIA3 通过选择性巨自噬/自噬途径靶向赖氨酸 332 介导狂犬病病毒 G 蛋白的降解;PDIA3 的相互作用物 AP3B1(衔接蛋白相关复合物 3 亚基β 1)对于 PDIA3 触发的 G 蛋白选择性降解是不可或缺的;此外,PDIA3 通过竞争性结合 NCAM1/NCAM(神经细胞粘附分子 1)来阻止狂犬病病毒 G 蛋白,阻止病毒进入宿主细胞。PDIA3 的 190-199 个氨基酸残基与狂犬病病毒 G 蛋白结合是抵抗狂犬病病毒所必需的,足以抵抗狂犬病病毒。这些结果表明,针对 PDIA3 的生物制剂或利用 PDIA3 的 190-199 个氨基酸肽治疗临床狂犬病具有治疗潜力。aa:氨基酸;ANXA2:膜联蛋白 A2;AP-MS:亲和标签纯化质谱;AP3B1:衔接蛋白相关复合物 3 亚基β 1;ATP6V1A:ATP 酶 H 转运 V1 亚基 A;ATP6V1H:ATP 酶 H 转运 V1 亚基 H;BafA1:巴弗霉素 A1;CHX:环己酰亚胺;co-IP:共免疫沉淀;DDX17:DEAD 盒解旋酶 17;DmERp60:内质网 p60;EBOV:扎伊尔埃博拉病毒;EV:空载体;GANAB:葡糖苷酶 IIα 亚基;G 蛋白:糖蛋白;GRM2/mGluR2:谷氨酸代谢型受体 2;HsPDIA3:蛋白二硫键异构酶家族 A 成员 3;IAV:流感病毒;ILF2:白细胞介素增强结合因子 2;KO:敲除;MAGT1:镁转运蛋白 1;MAP1LC3/LC3:微管相关蛋白 1 轻链 3;MmPDIA3:蛋白二硫键异构酶相关 3;NCAM1/NCAM:神经细胞粘附分子 1;NGFR/p75NTR:神经生长因子受体;NGLY1:N-糖基酶 1;OTUD4:OTU 去泛素酶 4;PDI:蛋白二硫键异构酶;PPIs:蛋白质-蛋白质相互作用;RABV:狂犬病病毒;RUVBL2:RuvB 样 AAA ATP 酶 2;SCAMP3:分泌载体膜蛋白 3;ScPdi1:S 蛋白二硫键异构酶 1;SLC25A6:溶质载体家族 25 成员 6;SQSTM1/p62:自噬体相关蛋白 1;VSV:水疱性口炎病毒。